Literature DB >> 22615012

Expression and clinical significance of UCH37 in human esophageal squamous cell carcinoma.

Yanjie Chen1, Da Fu, Junjie Xi, Zongfei Ji, Taotao Liu, Yushui Ma, Yuan Zhao, Ling Dong, Qun Wang, Xizhong Shen.   

Abstract

BACKGROUND: Ubiquitin carboxyl-terminal hydrolase 37 (UCH37), a member of the DUBs, was found to play an important role in oncogenesis through promoting some Proto-oncogenes' expression and stem cell-like characteristics in the cell in previous research. The aim of this study was to assess the value of UCH37 in predicting tumor recurrence after curative resection in esophageal squamous cell carcinoma (ESCC) patients.
METHODS: We analyzed UCH37 protein expression in 111 clinicopathologically characterized ESCC cases, from those who underwent curative resection between 2007 and 2008, by immunohistochemistry. The prognostic significance was assessed using Kaplan-Meier survival estimates and log-rank tests.
RESULTS: We found that UCH37 expression was higher in the cancer tissue than in non-tumorous control tissue at protein level and was overexpressed in tumor tissues of recurrent patients. There was a significant difference of UCH37 expression in patients categorized according to TNM stage (p = 0.038) and lymph nodes metastasis condition (p = 0.009). Univariate analyses revealed that UCH37 was a significant predictor for overall survival and disease-free survival, and multivariate analyses showed that UCH37 was an independent prognostic marker for ESCC recurrence. A prognostic significance of UCH37 was also found in the subgroup of lymph nodes metastasis condition classification. About 90 % of the recurrent patients recurred within 2 years, of which 84.4 % were predicted by UCH37.
CONCLUSION: UCH37 is associated with outcome and recurrence of ESCC and can be a novel predictor for poor prognosis of ESCC patients after curative resection.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22615012     DOI: 10.1007/s10620-012-2181-9

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  24 in total

Review 1.  The ubiquitin system.

Authors:  A Hershko; A Ciechanover
Journal:  Annu Rev Biochem       Date:  1998       Impact factor: 23.643

2.  Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world.

Authors:  Farin Kamangar; Graça M Dores; William F Anderson
Journal:  J Clin Oncol       Date:  2006-05-10       Impact factor: 44.544

3.  The interaction between ubiquitin C-terminal hydrolase 37 and glucose-regulated protein 78 in hepatocellular carcinoma.

Authors:  Ying Fang; Jingui Mu; Yushui Ma; Duan Ma; Da Fu; Xizhong Shen
Journal:  Mol Cell Biochem       Date:  2011-07-29       Impact factor: 3.396

4.  Proteasome recruitment and activation of the Uch37 deubiquitinating enzyme by Adrm1.

Authors:  Tingting Yao; Ling Song; Wei Xu; George N DeMartino; Laurence Florens; Selene K Swanson; Michael P Washburn; Ronald C Conaway; Joan Weliky Conaway; Robert E Cohen
Journal:  Nat Cell Biol       Date:  2006-08-13       Impact factor: 28.824

5.  hRpn13/ADRM1/GP110 is a novel proteasome subunit that binds the deubiquitinating enzyme, UCH37.

Authors:  Xiao-Bo Qiu; Song-Ying Ouyang; Chao-Jun Li; Shiying Miao; Linfang Wang; Alfred L Goldberg
Journal:  EMBO J       Date:  2006-11-30       Impact factor: 11.598

6.  Activity profiling of deubiquitinating enzymes in cervical carcinoma biopsies and cell lines.

Authors:  Ulrika Rolén; Vera Kobzeva; Natalja Gasparjan; Huib Ovaa; Gösta Winberg; Fjodor Kisseljov; Maria G Masucci
Journal:  Mol Carcinog       Date:  2006-04       Impact factor: 4.784

Review 7.  The potential role of ubiquitin c-terminal hydrolases in oncogenesis.

Authors:  Ying Fang; Da Fu; Xi-Zhong Shen
Journal:  Biochim Biophys Acta       Date:  2010-03-17

8.  The deubiquitinating enzyme UCH37 interacts with Smads and regulates TGF-beta signalling.

Authors:  Stephen J Wicks; Katherine Haros; Marjorie Maillard; Ling Song; Robert E Cohen; Peter Ten Dijke; Andrew Chantry
Journal:  Oncogene       Date:  2005-12-01       Impact factor: 9.867

9.  Regulators of the proteasome pathway, Uch37 and Rpn13, play distinct roles in mouse development.

Authors:  Amin Al-Shami; Kanchan G Jhaver; Peter Vogel; Carrie Wilkins; Juliane Humphries; John J Davis; Nianhua Xu; David G Potter; Brenda Gerhardt; Robert Mullinax; Cynthia R Shirley; Stephen J Anderson; Tamas Oravecz
Journal:  PLoS One       Date:  2010-10-27       Impact factor: 3.240

Review 10.  Deubiquitylating enzymes and disease.

Authors:  Shweta Singhal; Matthew C Taylor; Rohan T Baker
Journal:  BMC Biochem       Date:  2008-10-21       Impact factor: 4.059

View more
  36 in total

1.  Structures of Rpn1 T1:Rad23 and hRpn13:hPLIC2 Reveal Distinct Binding Mechanisms between Substrate Receptors and Shuttle Factors of the Proteasome.

Authors:  Xiang Chen; Leah Randles; Ke Shi; Sergey G Tarasov; Hideki Aihara; Kylie J Walters
Journal:  Structure       Date:  2016-07-07       Impact factor: 5.006

Review 2.  Ubiquitin proteasome system research in gastrointestinal cancer.

Authors:  Jia-Ling Zhong; Chang-Zhi Huang
Journal:  World J Gastrointest Oncol       Date:  2016-02-15

3.  Expression and clinical significance of BIRC6 in human epithelial ovarian cancer.

Authors:  Lin Wang; Yan-Jie Chen; Jun Hou; Ya-Yun Wang; Wen-Qing Tang; Xi-Zhong Shen; Rui-Qin Tu
Journal:  Tumour Biol       Date:  2014-01-23

4.  Phosphorylation of Tyr-950 in the proteasome scaffolding protein RPN2 modulates its interaction with the ubiquitin receptor RPN13.

Authors:  Casey W Hemmis; Stephanie C Heard; Christopher P Hill
Journal:  J Biol Chem       Date:  2019-05-07       Impact factor: 5.157

5.  High expression of UCH37 is significantly associated with poor prognosis in human epithelial ovarian cancer.

Authors:  Lin Wang; Yan-Jie Chen; Kai Xu; Ya-Yun Wang; Xi-Zhong Shen; Rui-Qin Tu
Journal:  Tumour Biol       Date:  2014-08-15

6.  The Proteasome Ubiquitin Receptor hRpn13 and Its Interacting Deubiquitinating Enzyme Uch37 Are Required for Proper Cell Cycle Progression.

Authors:  Leah Randles; Ravi K Anchoori; Richard B S Roden; Kylie J Walters
Journal:  J Biol Chem       Date:  2016-02-23       Impact factor: 5.157

7.  IRF-2 Inhibits Gastric Cancer Invasion and Migration by Down-Regulating MMP-1.

Authors:  Yan-Jie Chen; Li Liang; Jing Li; Hao Wu; Ling Dong; Tao-Tao Liu; Xi-Zhong Shen
Journal:  Dig Dis Sci       Date:  2019-07-26       Impact factor: 3.199

Review 8.  Deubiquitinases (DUBs) and DUB inhibitors: a patent review.

Authors:  Pershang Farshi; Rahul R Deshmukh; Joseph O Nwankwo; Richard T Arkwright; Boris Cvek; Jinbao Liu; Q Ping Dou
Journal:  Expert Opin Ther Pat       Date:  2015-06-16       Impact factor: 6.674

9.  A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance.

Authors:  Ze Tian; Padraig D'Arcy; Xin Wang; Arghya Ray; Yu-Tzu Tai; Yiguo Hu; Ruben D Carrasco; Paul Richardson; Stig Linder; Dharminder Chauhan; Kenneth C Anderson
Journal:  Blood       Date:  2013-12-06       Impact factor: 22.113

10.  Structural basis for the activation and inhibition of the UCH37 deubiquitylase.

Authors:  Ryan T Vander Linden; Casey W Hemmis; Benjamin Schmitt; Ada Ndoja; Frank G Whitby; Howard Robinson; Robert E Cohen; Tingting Yao; Christopher P Hill
Journal:  Mol Cell       Date:  2015-02-19       Impact factor: 17.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.